Category: ccRCC

UC2288 is an Orally Active p21 Attenuator

p21 is a member of the cip/kip family of cyclin-dependent kinase inhibitors, it regulates cell growth in both malignant or non-malignant cells. It possesses diverse physiological functions in vitro, such as vascular smooth muscle cell proliferation, cancer progression, and viral infection. p21 is well-known as a tumor suppressor protein...

PT2977 is an Orally Active and Selective HIF-2α Inhibitor for Solid Tumor Treatment

Previous studies have demonstrated that hypoxia-inducible factor 2α (HIF-2α) is a key oncogenic driver in clear cell renal cell carcinoma (ccRCC). PT2385 was the first reported HIF-2α inhibitor. However, PT2385 was restricted by variable and dose-limited pharmacokinetics. This results from extensive metabolism of PT2385 to its glucuronide metabolite. Herein,...